P1241 | BEDSIDE. Everolimus and paclitaxel-eluting stents for small coronary artery diseases: insight from the one year results of PLUM and SACRA registries.
Interventional cardiology
P1241 | BEDSIDE Everolimus and paclitaxel-eluting stents for small coronary artery diseases: insight from the one year results of PLUM and SACRA registries K. Nasu 1 , Y. Oikawa 2 , M. Kadotani 3 , M. Tanabe 4 , Y. Takeda 5 , R. Kawaguchi 6 , T. Serikawa 7 , Y. Mibiki 8 , T. Suzuki 9 , T. Tsuji 10 on behalf of SACRA and PLUM Registries Investigators. 1 Toyohashi Heart Center, Toyohashi, Japan; 2 The Cardiovascular Institute Hospital, Tokyo, Japan; 3 Kakogawa East City Hospital, Kakogawa, Japan; 4 Daini Okamoto General Hospital, Uji, Japan; 5 Rinku General Medical Center, Izumisano, Japan; 6 Gunma Prefectural Cardiovascular Center, Maebashi, Japan; 7 Saiseikai Fukuoka General Hospital, Fukuoka, Japan; 8 Miyagi Cardiovascular and Respiratory Center, Kurihara, Japan; 9 JA Hokkaido Engaru Kosei General Hospital, Monbetsu, Japan; 10 Kusatsu Heart Center, Kusatsu, Japan Purpose: Percutaneous coronary interventions involving small coronary vessels represent a true challenge because of the increased risk of restenosis and adverse outcomes. The aim of this study is to evaluate the one-year clinical results following small coronary stenting between everolimus- (EES) and paclitaxeleluting stent (PES). Methods: PLUM (PROMUS/Xience V Everolimus-ELUting Coronary Stent for sMall coronary artery disease: 264 patients with 279 lesions) and SACRA (SmAll CoronaRy Artery treated by TAXUS Liberté: 245 patients with 258 lesions) registries are prospective, multicenter registries to assess the efficacy of single EES and PES in patients with small coronary artery diseases. Inclusion criteria were 1) Lesions >75% diameter stenosis in vessels
